Autologous dendritic cell transplantation as an adjuvant treatment in pleomorphic lung carcinoma
Acta Medica Philippina
We embarked on autologous dendritic cells (DC) transplantation as an adjuvant therapy with chemotherapy in a pleomorphic lung carcinoma patient. DC were isolated from PBMC and primed with the autologous tumor lysate. No adverse event was noted in DC transplantation. DC administration also correlated with immunomodulation, as evidenced by an approximately 5-fold increase in serum interferon gamma after 2 months. The utility of autologous DC transplantation may offer a clinical benefit with virtually no adverse event.
Chung, F., Tan-Liu, N., Ladrera, G., Habaluyas, R., Yuson, E., Danguilan, J., Bernal, S., Rubio, J., & Barzaga, M. (2013). Autologous dendritic cell transplantation as an adjuvant treatment in pleomorphic lung carcinoma. Acta Medica Philippina, 47(4), 72-75. DOI:10.47895/amp.v47i4.1273